Novartis | NOVN - Cost Of Sales


Novartis reported $3.46B in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Alcon AG USD 1.18B 26M Mar/2026
Almirall EUR 191.5M 2.29M Dec/2025
Amgen USD 1.6B 187M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
Autolus Therapeutics Ltd USD 24.57M 762K Mar/2026
Bayer EUR 5.23B 731M Mar/2026
Biogen USD 797.5M 302M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Fresenius EUR 4.45B 262M Dec/2025
Fresenius Medical Care EUR 3.43B 248M Mar/2026
Genmab DKK 81M 23M Dec/2025
Gilead Sciences USD 1.44B 174M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
GRIFOLS EUR 1.08B 214.82M Mar/2026
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
J&J USD 8B 67M Jun/2026
Lakefront Biotherapeutics EUR 4.8M 4.34M Mar/2026
Lonza CHF 2.28B 189M Jun/2025
Merck EUR 2.07B 219M Mar/2026
Merck USD 2.94B 380M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Novo Nordisk DKK 13.6B 1.55B Mar/2026
Orion EUR 181.7M 18M Jun/2026
Pfizer USD 4.59B 1.7B Mar/2026
Philips EUR 2.14B 669M Mar/2026
Recordati EUR 202.6M 13.03M Mar/2026
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 3.67B 621M Mar/2026
UCB EUR 1.07B 146M Dec/2025